Management of miscarriage: expectant, medical, or surgical? Results of randomised controlled trial (miscarriage treatment (MIST) trial)

J Trinder, P Brocklehurst, R Porter, M Read, S Vyas, L Smith

Abstract

Objective To ascertain whether a clinically important difference exists in the incidence of gynaecological infection between surgical management and expectant or medical management of miscarriage.

Design Randomised controlled trial comparing medical and expectant management with surgical management of first trimester miscarriage.

Setting Early pregnancy assessment units of seven hospitals in the United Kingdom.

Participants Women of less than 13 weeks' gestation, with a diagnosis of early fetal demise or incomplete miscarriage.

Interventions Expectant management (no specific intervention); medical management (vaginal dose of misoprostol 24-48 hours earlier); surgical management (surgical evacuation).

Main outcome measures Confirmed gynaecological infection at 14 days and eight weeks; need for unplanned admission or surgical intervention.

Results 1200 women were recruited: 399 to expectant management, 398 to medical management, and 403 to surgical management. No differences were found in the incidence of confirmed infection within 14 days between the expectant group (3%) and the surgical group (3%) (risk difference 0.2%, 95% confidence interval −2.2% to 2.7%) or between the medical group (2%) and the surgical group (0.7%, −1.6% to 3.1%). Compared with the surgical group, the number of unplanned hospital admissions was significantly higher in both the expectant group (risk difference −41%, −47% to −36%) and the medical group (−10%, −15% to −6%). Similarly, when compared with the surgical group, the number of women who had an unplanned surgical curettage was significantly higher in the expectant group (risk difference −39%, −44% to −34%) and the medical group (−30%, −35% to −25%).

Conclusions The incidence of gynaecological infection after surgical, expectant, and medical management of first trimester miscarriage is low (2-3%), and no evidence exists of a difference by the method of management. However, significantly more unplanned admissions and unplanned surgical curettage occurred after expectant management and medical management than after surgical management.

Trial registration National Research Register: N0467011677/N0467073587.
our study hypothesis was that a clinically important difference

**Methods**

This was a multicentre trial with seven participating hospitals, each of which had an early pregnancy clinic. Recruitment started in May 1997 and finished in December 2001. Written consent was obtained for each patient.

**Eligibility criteria**

Women with a pregnancy of less than 13 weeks’ gestation who had been diagnosed as having either an incomplete miscarriage or early fetal/embryonic demise were eligible. Exclusion criteria were severe haemorrhage or pain, pyrexia above 37.5°C, severe asthma, haemolytic disease or blood dyscrasias, current anticoagulation or systemic corticosteroid treatment, twin or higher order pregnancy, smoker aged over 35, and inability to understand written English.

We defined early embryonic demise as an intact gestation sac of greater than 20 mm mean diameter with no other internal structures and early fetal demise as a fetus of over 6 mm crown-rump length with no heart activity on transvaginal ultrasound scan. We defined an incomplete miscarriage as areas of mixed echogenicity within the uterine cavity with or without a disordered gestation sac.

**Randomisation and blinding**

Randomisation was by a central telephone system at the Clinical Trials Services Unit, Oxford. We used minimisation to ensure comparability between women with respect to participating centre, parity, type of miscarriage, and gestation.

**Interventions**

We gave all women a specific information sheet, 30 co-dydramol tablets, and an emergency telephone number. Women in the expectant management arm were allowed home with no intervention. In the medical management arm, women with an incomplete miscarriage were admitted to hospital and given a single vaginal dose of 800 µg misoprostol. Women with early fetal or embryonic demise were pre-treated with a single oral dose of 200 mg mifepristone, then admitted to hospital 24-48 hours later for a single vaginal dose of 800 µg misoprostol. A surgical evacuation of retained products of conception was offered if expulsion of retained products had not started within eight hours of insertion of misoprostol. Women in the surgical management arm were admitted for surgical suction curettage under general anaesthesia. No centre used prophylactic antibiotics at the time of curettage.

In all three groups, blood was taken for full blood count. Rhesus negative women were offered 250 IU of anti-D irrespective of their allocated management. A follow-up appointment was arranged 10-14 days after trial entry for a transvaginal ultrasound scan, full blood count, consultation with the study nurse, and examination by a gynaecologist if symptoms of infection were present. Retained products of conception were diagnosed if areas of mixed echogenicity within the uterine cavity were seen. A surgical curettage was offered if retained products of conception were present. Clinical symptoms were also taken into account; individual doctors in the early pregnancy clinics made the decision to offer curettage, in association with the women.

**Study hypothesis**

Our study hypothesis was that a clinically important difference would exist in documented gynaecological infection within 14 days of expectant or medical management compared with surgical management of first trimester miscarriage.

**Outcomes**

The primary outcome was documented gynaecological infection within 14 days of trial entry, defined as two or more of purulent vaginal discharge, pyrexia > 38.0°C, tenderness over the uterus on abdominal examination, and a white cell count above 15×10^9/L. Secondary outcomes were treatment with antibiotics for presumed gynaecological infection within 14 days and within eight weeks; duration of clinical symptoms (pain, additional analgesia, vaginal bleeding, days off work, days before return to usual daily activities); complications (fall in haemoglobin at 10-14 days, blood transfusion, unplanned consultations or admissions within 14 days and within eight weeks); efficacy—we defined a successful outcome as no unplanned surgical curettage within eight weeks; psychological outcomes (depression and anxiety on the hospital anxiety and depression scale at eight weeks); and return to normal activity (standard UK SF-36).

**Sample size estimation**

On the basis of the one published trial before the MIST trial started, we expected the incidence of the primary outcome in the standard care group (surgical management) to be 10%. To detect a 50% lower incidence of this outcome in the surgical group, compared with the expectant or medical management group, we needed to recruit 474 women to each group, giving a total sample size of 1422 women. This sample size would have 80% power to detect the treatment effect significant at the 5% level.

**Statistical methods**

We used SPSS to analyse data. We express the differences between groups as risk differences with 95% confidence intervals.

**Trial management**

A research fellow (JT) based at one of the centres coordinated the day to day activity of the seven participating centres. Randomisation, data management, and analyses were done at the National Perinatal Epidemiology Unit, Oxford. A multidisciplinary steering committee oversaw the trial. We established an independent data monitoring committee, which met annually during the period of recruitment to review interim analyses; its terms of reference stated that interim results should not be revealed to the steering committee unless a strong reason to alter the protocol or stop the trial emerged.

**Results**

**Participant recruitment, flow, and follow-up**

Of 3905 women attending the early pregnancy clinics, we recruited and randomised 1200 (31%) women (figure); 1620 women refused trial entry and were offered routine surgical management; 1085 women were not eligible for entry to the study. The number of women recruited to the trial was lower than that needed to meet the original sample size calculation. Recruitment was slower than anticipated and despite an additional 33 months of recruitment, we recruited a total of 1200 women. Two women recruited to the trial were subsequently found to have a viable pregnancy. No important baseline differences were evident between the three groups (table 1).

Of the 402 women randomised to surgical management, 356 (89%) had a surgical curettage. Among the 46 women who did not have elective curettage, 30 (8%) miscarried before admission and 16 (4%) declined to have curettage after randomisation;
however, 12 (3%) subsequently had curettage. In 12 (3%) women in the medical group, the miscarriage occurred spontaneously before admission (2 (0.5%) subsequently had curettage).

Gynaecological infection
We found no difference in the primary outcome measure—that is, the incidence of infection within the first 14 days—between the expectant group and the surgical group or between the medical group and the surgical group 3% (12/402), expectant group 3% (11/398), medical group 2% (9/398) (table 2). The incidence of infection defined as prescription of antibiotic for presumed gynaecological infection within the first 14 days was significantly lower in the expectant group (17/398) compared with the surgical group (34/402) (risk difference 4%, 95% confidence interval 1% to 8%). The incidence of this outcome in the medical group (31/398) was not significantly different from that in the surgical group (risk difference 1%, −3% to 5%). We found no significant difference at eight weeks for either group compared with the surgical group.

Unplanned hospital consultation and admissions
The number of unplanned hospital consultations (without admission), both within the first 14 days after randomisation and within the first eight weeks, was similar for all management groups. However, the number of unplanned hospital admissions was significantly higher in the expectant group (196, 49%) than in the surgical group (32, 8%) (risk difference −41%, −47% to −0%).

Table 2  Clinical outcomes. Values are numbers (percentages) unless stated otherwise

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Surgical (n=402)</th>
<th>Expectant (n=398)</th>
<th>Surgical−expectant % risk difference (95% CI)</th>
<th>Medical (n=398)</th>
<th>Surgical−medical risk difference (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infection specified by criteria:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>By 10-14 day follow-up</td>
<td>12 (3)</td>
<td>11 (3)</td>
<td>0.2 (−2.2 to 2.7)</td>
<td>9 (2)</td>
<td>0.7 (−1.6 to 3.1)</td>
</tr>
<tr>
<td>By 8 week follow-up</td>
<td>16 (4)</td>
<td>14 (4)</td>
<td>0.5 (−2.3 to 3.2)</td>
<td>12 (3)</td>
<td>1.0 (−1.7 to 3.7)</td>
</tr>
<tr>
<td>Infection specified by antibiotic use:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>By 10-14 day follow-up</td>
<td>34 (8)</td>
<td>17 (4)</td>
<td>4.2 (0.8 to 7.7)</td>
<td>31 (8)</td>
<td>0.7 (−3.2 to 4.5)</td>
</tr>
<tr>
<td>By 8 week follow-up</td>
<td>44 (11)</td>
<td>31 (8)</td>
<td>3.2 (−0.9 to 7.3)</td>
<td>43 (11)</td>
<td>0.1 (−4.2 to 4.5)</td>
</tr>
<tr>
<td>10-14 day follow-up ultrasound scan:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Evidence of RPOC</td>
<td>41 (10)</td>
<td>145 (36)</td>
<td>−26.2 (−31.7 to −20.6)</td>
<td>78 (20)</td>
<td>−9.4 (−14.3 to −4.5)</td>
</tr>
<tr>
<td>Equivalent result</td>
<td>53 (13)</td>
<td>42 (11)</td>
<td>2.6 (−1.9 to 7.1)</td>
<td>52 (13)</td>
<td>0.1 (−4.6 to 4.8)</td>
</tr>
<tr>
<td>Empty uterus</td>
<td>271 (67)</td>
<td>185 (46)</td>
<td>20.9 (14.1 to 27.5)</td>
<td>240 (60)</td>
<td>7.1 (0.5 to 13.7)</td>
</tr>
<tr>
<td>No follow-up scan</td>
<td>37 (9)</td>
<td>26 (7)</td>
<td>2.7 (−1.1 to 6.5)</td>
<td>28 (7)</td>
<td>2.2 (−1.7 to 6.0)</td>
</tr>
<tr>
<td>Median (interquartile range) duration of bleeding (days)</td>
<td>8 (4-14)</td>
<td>12 (7-15)</td>
<td>11 (7-15)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood transfusion</td>
<td>0</td>
<td>7 (2)</td>
<td>−1.8 (−3.6 to −0.4)</td>
<td>4 (1)</td>
<td>−1.0 (−2.6 to 0.4)</td>
</tr>
<tr>
<td>Extra analgesia taken</td>
<td>71 (18)</td>
<td>177 (44)</td>
<td>−26.8 (−32.8 to −20.5)</td>
<td>98 (25)</td>
<td>−7.8 (−12.6 to −3.0)</td>
</tr>
</tbody>
</table>

RPOC=retained products of conception.
– 36%) and was also higher in the medical group (72, 18%) (– 10%, – 15% to – 6%).

Unplanned curettage

Table 3 shows the number of women who had unplanned surgical curettage and the indications. One hundred and forty two (36%) women randomised to medical management had surgical curettage compared with 22 (5%) women who had unplanned curettage in the surgical group (risk difference – 30%, – 35% to – 25%). Of 142 women in the medical group who had curettage, the indication for this was failure of the medical management protocol in 90 (23%). A further 52 (13%) women had an unplanned curettage, 11 (3%) as an emergency procedure before anticipated admission.

The type of miscarriage was a factor in the success of management. Twenty (6%) women with early fetal demise who were allocated to the surgical group had an unplanned curettage, compared with a total of 116 (38%) of the medical group (risk difference – 31%, – 37% to – 25%) and 154 (50%) of the expectant group (– 44%, – 50% to – 37%) (table 4). Of women with an incomplete miscarriage, 2 (2%) in the surgical group had an unplanned curettage compared with a total of 26 (29%) in the medical group (risk difference – 27%, – 37% to – 17%) and 23 (25%) in the expectant group (– 23, – 33% to – 13%) (table 5).

Clinical symptoms, complications, and side effects

Cessation of bleeding after randomisation was significantly earlier in the surgical group than in the medical group (P = 0.0004) and the expectant group (P < 0.0001), but this did not affect haemoglobin concentration and haematocrit at 10-14 days. However, 7 (2%) women randomised to expectant management and 4 (1%) women randomised to medical management had a blood transfusion. No women randomised to surgical management had transfusions.

We found no significant difference in vomiting, diarrhoea, or pain (when assessed by the medical staff) in the medical group compared with the surgical group. We used the outcome of

Table 4 Selected outcomes for women with early fetal demise. Values are numbers (percentages) unless stated otherwise

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Surgical (n=310)</th>
<th>Expectant (n=306)</th>
<th>Surgical–expectant % risk difference (95% CI)</th>
<th>Medical (n=308)</th>
<th>Surgical–medical % risk difference (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infection specified by criteria:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>By 10-14 day follow-up</td>
<td>9 (3)</td>
<td>9 (3)</td>
<td>0 (-2.9 to 2.8)</td>
<td>7 (2)</td>
<td>0.06 (-2.1 to 3.4)</td>
</tr>
<tr>
<td>By 8 week follow-up</td>
<td>13 (4)</td>
<td>12 (4)</td>
<td>0.03 (-0.3 to 3.6)</td>
<td>9 (3)</td>
<td>1.3 (-1.8 to 4.4)</td>
</tr>
<tr>
<td>Infection specified by antibiotic use:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>By 10-14 day follow-up</td>
<td>28 (9)</td>
<td>15 (5)</td>
<td>3.5 (-0.05 to 7.6)</td>
<td>25 (8)</td>
<td>0.03 (-4.2 to 4.7)</td>
</tr>
<tr>
<td>By 8 week follow-up</td>
<td>33 (11)</td>
<td>28 (9)</td>
<td>1.5 (-3.3 to 6.3)</td>
<td>34 (11)</td>
<td>-0.04 (-5.4 to 4.6)</td>
</tr>
<tr>
<td>No of women who had any curettage*</td>
<td>278 (94)</td>
<td>154 (50)</td>
<td>39.4 (32.8 to 45.6)</td>
<td>116 (38)</td>
<td>52.0 (45.3 to 58.0)</td>
</tr>
<tr>
<td>No of women who had one or more unplanned curettage†</td>
<td>26 (8)</td>
<td>154 (50)</td>
<td>-43.9 (-49.9 to -37.4)</td>
<td>46 (15)</td>
<td>-8.5 (-13.4 to -3.6)</td>
</tr>
<tr>
<td>Main reason for unplanned consultation resulting in first unplanned curettage:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Excess bleeding</td>
<td>5 (2)</td>
<td>15 (5)</td>
<td>-3.3 (-6.5 to 0.04)</td>
<td>12 (4)</td>
<td>-2.3 (-5.2 to 0.04)</td>
</tr>
<tr>
<td>Pain</td>
<td>3 (1)</td>
<td>5 (2)</td>
<td>0.07 (-2.9 to 1.4)</td>
<td>3 (1)</td>
<td>0 (-2.9 to 1.9)</td>
</tr>
<tr>
<td>Patient request</td>
<td>2 (1)</td>
<td>52 (17)</td>
<td>-16.3 (-21.0 to -11.2)</td>
<td>8 (3)</td>
<td>-2.0 (-4.4 to 0.2)</td>
</tr>
<tr>
<td>Retained products on scan</td>
<td>8 (3)</td>
<td>64 (21)</td>
<td>-18.3 (-23.4 to -13.5)</td>
<td>21 (7)</td>
<td>-4.2 (-7.8 to -0.6)</td>
</tr>
<tr>
<td>Other</td>
<td>2 (1)</td>
<td>17 (6)‡</td>
<td>-4.9 (-8.81 to -2.3)</td>
<td>2 (1)</td>
<td>0 (-1.8 to 1.7)</td>
</tr>
<tr>
<td>No of women having more than one unplanned curettage</td>
<td>2 (1)</td>
<td>10 (3)</td>
<td>-2.6 (-5.3 to -0.04)</td>
<td>2 (1)</td>
<td>0 (-1.8 to 1.7)</td>
</tr>
<tr>
<td>Median (interquartile range) duration of bleeding (days)</td>
<td>9 (4-14)</td>
<td>12 (7-16)</td>
<td></td>
<td>11 (7-15)</td>
<td></td>
</tr>
<tr>
<td>Blood transfusion</td>
<td>0</td>
<td>7 (2)</td>
<td></td>
<td>3 (1)</td>
<td></td>
</tr>
<tr>
<td>Extra analgesia taken</td>
<td>59 (19)</td>
<td>156 (51)</td>
<td>-31.9 (-38.8 to -24.6)</td>
<td>82 (27)</td>
<td>-7.6 (-14.1 to -1.0)</td>
</tr>
</tbody>
</table>

*Allocated, for failed medical induction, or unplanned.
†Excluding women who had curettage for failure of medical management protocol.
‡One not known.
“extra analgesia” as a proxy measure to evaluate the need for analgesia by all three groups in the outpatient setting. The expectant management group received significantly more analgesia (table 2).

We found no difference between the three groups in the incidence of surgical complications in the women who had surgery. Surgical complications were reported in 2% (9/402), 1% (4/398), and 1% (4/398) of women allocated to receive surgical, expectant, and medical management respectively.

**Psychological and activities outcomes**

In all three groups the median time to return to usual daily activities was two days. Sick leave was also similar in all three groups—the median was nine days in the surgical group, eight days in the expectant group, and nine days in the medical group. No differences existed in anxiety or depression scores on the hospital anxiety and depression questionnaire six to eight weeks after miscarriage. Similarly, no differences existed in activities of daily living on any of the eight subscales of the UK SF-36.

**Discussion**

Gynaecologists have been taught that surgical curettage is necessary to prevent infection after miscarriage. In this trial, the infection rates after expectant, medical, and surgical management were not significantly different and were reassuringly low. This was in the absence of screening for infection and without the use of prophylactic antibiotics. Moreover, the incidence of presumed infection as measured by antibiotic prescription in the first 14 days was significantly lower in the expectant management group than in the surgical group. These data should be reassuring to people who have raised concern about the lack of evidence available for non-surgical treatment of miscarriage. 3,4

The success rates in this trial were comparable to those in other trials of expectant management of incomplete miscarriage and early fetal demise. 5,6,7 Observational studies, however, had suggested that higher success rates were achievable. 8,9 Some of these differences could be explained by the lack of a universal definition of ultrasound scan findings of incomplete miscarriage or the presence of retained products at follow-up. Current clinical practice is not to do an ultrasound scan to measure endometrial thickness after a surgical curettage. Therefore, more women than usual may have been diagnosed as having retained products of conception and advised to have subsequent surgical curettage. For medical management, the success of the treatment protocol was disappointing compared with the higher success rates in the observational studies on which we based the treatment protocol and other observational studies. 10 11

Women are increasingly offered a choice of treatment for the management of miscarriage. 12 This study provides important data to enable women to be informed about their treatment choice. The ability of a unit to offer all three choices will depend on its facilities. The unplanned admission rate in women randomised to expectant management supports the advice from the Royal College of Obstetricians and Gynaecologists that expectant and medical management should be offered only in units where patients have access to 24 hour telephone advice and immediate admission can be arranged. 13 Expectant management seems to be particularly appropriate for incomplete miscarriage, with success rates of 75%, although an emergency admission rate of up to 29% should be anticipated.

Medical management does not seem to offer greater success than expectant management when used to treat incomplete miscarriage, but it may offer an alternative management in early fetal demise. Allowing a longer time for products of conception to pass may increase the success rate. 14 However, the increased time spent in hospital could be unattractive to women and care providers alike. Another option would be to use misoprostol in an outpatient setting. Randomised trials have shown that this is possible, with success rates of 72-93%. 15 16 17 18 19 20 21 22 23 24 25 The optimum regimen for medical management is yet to be devised, and further research is needed to determine this, particularly in an outpatient setting. Surgical curettage still offers the greatest complete evacuation rate, the least risk of needing unplanned admission, and the shortest duration of bleeding. It should therefore continue to be offered as a management option, particularly to those women with early fetal demise.

Because of the challenges of recruiting women to a trial of expectant, medical, and surgical management of miscarriage of...
this size, such a trial seems unlikely to be repeated. This trial shows that infection rates, whatever the chosen management, are reassuringly low. Success rates of the three options may be higher than the MIST trial suggests, as women who choose a treatment option are likely to be more motivated to follow their chosen treatment to completion than are women who are randomised.12

We thank the Clinical Trials Service Unit, Oxford, for providing telephone randomisation and Sarah Ayers at the National Perinatal Epidemiology Unit, Oxford, for writing the data entry program and for providing data for analysis. We also thank Steering Committee members G Stirrat (Bristol), D Mant (Oxford), R Bender Atkin (Miscarriage Association), and C Law (Southampton) for their guidance during the trial and Data Monitoring Committee members D Elbourne (London), D Jewell (Bristol), P Ewings (Taunton), and J Friend (Plymouth). A list of investigators and centres is on bmj.com.

Contributors: JT, PB, and LS prepared the manuscript. JT, RP, SV, and LS designed and coordinated the trial, JT, LS, and PB coordinated the data collection. PB did the statistical analysis. JT is the guarantor.

Funding: The MIST study was funded by a South and West NHS Executive research and development grant. A donation of £20 000 was accepted from Exelgen. Neither the NHS Executive nor Exelgen had any role in the study design; collection, analysis, or interpretation of data; writing of the report; or the decision to submit the paper for publication.

Competing interests: The study group accepted a donation of £20 000 from Exelgen, the manufacturers of mifepristone. The authors have no other competing interests.

Ethical approval: Multicentre Research Ethics Committee (MREC/97/6/competing interests. Exelgen, the manufacturers of mifepristone. The authors have no other competing interests: The study group accepted a donation of £20 000 from Exelgen. Neither the NHS Executive nor Exelgen had any role in the study design. We also thank the members D Elbourne (London), D Jewell (Bristol), P Ewings (Taunton), and J Friend (Plymouth). A list of investigators and centres is on bmj.com.

Contributors: JT, PB, and LS prepared the manuscript. JT, RP, SV, and LS designed and coordinated the trial, JT, LS, and PB coordinated the data collection. PB did the statistical analysis. JT is the guarantor.

Funding: The MIST study was funded by a South and West NHS Executive research and development grant. A donation of £20 000 was accepted from Exelgen. Neither the NHS Executive nor Exelgen had any role in the study design; collection, analysis, or interpretation of data; writing of the report; or the decision to submit the paper for publication.

Competing interests: The study group accepted a donation of £20 000 from Exelgen, the manufacturers of mifepristone. The authors have no other competing interests.

Ethical approval: Multicentre Research Ethics Committee (MREC/97/6/24) and local research ethics committee approval for each centre.


What is already known on this topic

The most effective method of ensuring complete evacuation of retained products of conception after miscarriage is surgical curettage.

Expectant management of incomplete miscarriage is effective, and evidence suggests that it is associated with lower rates of infection than surgical management.

Medical management of miscarriage is effective, but little is known about infection rates.

What this study adds

The risk of gynaecological infection after management of miscarriage by expectant, medical, and surgical methods is known about infection rates. The most effective method of ensuring complete evacuation of retained products of conception after incomplete miscarriage is surgical curettage.

Expectant management of incomplete miscarriage is effective, and evidence suggests that it is associated with lower rates of infection than surgical management.

Medical management of miscarriage is effective, but little is known about infection rates.

The risk of unplanned hospital admission is highest with medical, and surgical management of miscarriage.